ACE inhibition and mechanisms of skeletal muscle weakness in COPD

Phase 1

• Conditions: Chronic obstructive pulmonary disease patients who have skeletal muscle weakness.; MedDRA version: 9.1Level: LLTClassification code 10010952Term: COPD

• Registration Number: EUCTR2008-004431-38-GB
• Lead Sponsor: Imperial College

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-11-24
• Study Completion: 2012-12-03
• Last Update Posted: 13 October 2020

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Adult, consenting patient with COPD diagnosed according to GOLD criteria.
Quadriceps weakness defined as a force in Kg<120% of body mass index.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Clinically unstable patients (within one month of exacerbation), those with a permanent pacemaker (which is a contraindication to magnetic stimulation), or significant co-morbidity, patients with an accepted indication for ACE inhibition (left ventricular dysfunction, diabetes) or a contraindication such as renovascular disease; creatinine clearance (estimated) <50); hypotension; use of anticoagulants (contra-indication to biopsy) or ACE-I or ATII receptor antagonists.
Allergy to ACE-inhibitors.
Pregancy

Patients will not be enrolled within three months of participation in a pulmonary rehabilitation program.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified